PB2004: BCMA-DIRECTED THERAPY FOR MULTIPLE MYELOMA: EFFECTIVENESS OF ONLINE EDUCATION IN IMPROVING KNOWLEDGE AND COMPETENCE IN PRACTICAL APPLICATION

PB2004: BCMA-DIRECTED THERAPY FOR MULTIPLE MYELOMA: EFFECTIVENESS OF ONLINE EDUCATION IN IMPROVING KNOWLEDGE AND COMPETENCE IN PRACTICAL APPLICATION

Bibliographic Details
Main Authors:	V. Harvey-Jones, S. Koekkoek, J. Vandenbroucque, M.-V. Mateos
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000850848.93831.a6

Similar Items

BCMA-targeted immunotherapy for multiple myeloma
by: Bo Yu, et al.
Published: (2020-09-01)

The Gaining Momentum of BCMA-Directed Therapies for Relapsed/Refractory Multiple Myeloma
by: Adrian Schmidt
Published: (2023-10-01)

Single VHH-directed BCMA CAR-NK cells for multiple myeloma
by: Quan Ren, et al.
Published: (2023-11-01)

Anti-BCMA CAR T-cell Therapy: Changing the Natural History of Multiple Myeloma
by: Borja Puertas, et al.
Published: (2022-03-01)

PB1780: AN INNOVATIVE INTERACTIVE CASE-BASED ONLINE EDUCATION TOOL SUBSTANTIALLY INCREASES KNOWLEDGE AND COMPETENCE OF CLINICIANS MANAGING HIGH-RISK AML
by: V. Harvey-Jones, et al.
Published: (2022-06-01)

Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma
by: Benedetta Dalla Palma, et al.
Published: (2020-09-01)

BCMA in Multiple Myeloma—A Promising Key to Therapy
by: Martina Kleber, et al.
Published: (2021-09-01)

sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma
by: Katja Seipel, et al.
Published: (2022-03-01)

Outcomes of Penta-Refractory Multiple Myeloma Patients Treated with or without BCMA-Directed Therapy
by: Shebli Atrash, et al.
Published: (2023-05-01)

Non‐BCMA targeted CAR‐T cell therapies for multiple myeloma
by: Xiangmin Wang, et al.
Published: (2021-12-01)

Management of Adverse Reactions for BCMA-Directed Therapy in Relapsed Multiple Myeloma: A Focused Review
by: Razwana Khanam, et al.
Published: (2023-08-01)

Targeting BCMA in Multiple Myeloma: Advances in Antibody-Drug Conjugate Therapy
by: Lijie Xing, et al.
Published: (2023-04-01)

Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma
by: Gils Roex, et al.
Published: (2020-12-01)

Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
by: Fumou Sun, et al.
Published: (2024-01-01)

Role of Anti-B-Cell Maturation Antigen (BCMA) in the Management of Multiple Myeloma
by: Ikhwan Rinaldi, et al.
Published: (2022-07-01)

BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma
by: Shih-Feng Cho, et al.
Published: (2020-06-01)

Bispecific BCMA-CD3 Antibodies Block Multiple Myeloma Tumor Growth
by: Lijun Wu, et al.
Published: (2022-05-01)

Anti‐BCMA Immuno‐NanoPET Radiotracers for Improved Detection of Multiple Myeloma
by: Thomas, Eloise, et al.
Published: (2022)

Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study
by: Zimu Gong, et al.
Published: (2024-03-01)

CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond
by: Abhinava K. Mishra, et al.
Published: (2023-11-01)

B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies
by: Larysa Sanchez, et al.
Published: (2021-01-01)

Early Dynamics and Depth of Response in Multiple Myeloma Patients Treated With BCMA CAR-T Cells
by: Sandy W. Wong, et al.
Published: (2021-12-01)

T cells isolated from G-CSF-treated multiple myeloma patients are suitable for the generation of BCMA-directed CAR-T cells
by: Anthony M. Battram, et al.
Published: (2022-09-01)

Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients
by: A. Visram, et al.
Published: (2021-06-01)

Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma
by: Surbhi Sidana, et al.
Published: (2023-10-01)

Single-cell transcriptomic atlas throughout anti-BCMA CAR-T therapy in patients with multiple myeloma
by: Yuan Xia, et al.
Published: (2023-11-01)

CAR-T Cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell Growth
by: Robert Berahovich, et al.
Published: (2018-09-01)

Armored BCMA CAR T Cells Eliminate Multiple Myeloma and Are Resistant to the Suppressive Effects of TGF-β
by: Leah M. Alabanza, et al.
Published: (2022-02-01)

PB2134: BCMA-TARGETED THERAPIES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION – A SINGLE CENTER EXPERIENCE
by: Irene Strassl, et al.
Published: (2023-08-01)

Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma
by: Rebecca C. Larson, et al.
Published: (2023-11-01)

PB2031: CD269, CD319 EXPRESSION ON MALIGNANT PLASMA CELLS AND SOLUBLE BCMA, SLAMF7 PROTEINS COMPARATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
by: A. Startsev, et al.
Published: (2022-06-01)

The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma
by: Kai Rejeski, et al.
Published: (2023-07-01)

P855: FERROPTOSIS AS A NEW BCMA-TARGETED IMMUNOTHERAPY OFF-TARGET EFFECT IN MULTIPLE MYELOMA
by: Enrico La Spina, et al.
Published: (2023-08-01)

Genome-wide CRISPR/Cas9 screen identifies regulators of BCMA expression on multiple myeloma cells
by: Ram Ajore, et al.
Published: (2024-01-01)

Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance
by: Danilo De Novellis, et al.
Published: (2022-12-01)

271 Development and characterisation of humanised scFv CAR-T therapies targeting BCMA against multiple myeloma
by: Susana Inogés, et al.
Published: (2023-11-01)

Ex vivo efficacy of BCMA‐bispecific antibody TNB‐383B in relapsed/refractory multiple myeloma
by: David M. Foureau, et al.
Published: (2020-07-01)

Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma
by: Endeshaw Chekol Abebe, et al.
Published: (2022-09-01)

Clinical Outcomes of BCMA CAR-T Cells in a Multiple Myeloma Patient With Central Nervous System Invasion
by: Ting Wang, et al.
Published: (2022-05-01)

Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma
by: Mehmet Kemal Samur, et al.
Published: (2021-02-01)